MarketCap
Facebook
X
Telegram
Amicus Therapeutics Income Statement 2025-2011 | FOLD
Brief overview of profit and loss at Amicus Therapeutics
The comparison covers a five-year financial horizon. Revenue reported by Amicus Therapeutics was $261 million at the beginning of the period and $634 million at the end. Overall revenue changed by +143.1%, equal to an annualized rate of about 19.4%. Revenue followed a strong upward trend without signs of stagnation.
The five-year change in gross profit reached +144.2%: from $230 million to $561 million. The cost base moved more slowly than the top line, which supported margins. The gross margin was 88.1% at the start and 88.5% at the end. Gross profitability remained broadly stable.
The operating result measured by EBITDA moved from −238 million dollars to 40.2 million dollars, or +116.9%. Operating performance weakened relative to revenue. Comparing the endpoints gives EBITDA margins of −91.3% and 6.3%. The company improved its ability to convert sales into EBITDA.
Comparing the endpoints shows a move from −277 million dollars to −27.1 million dollars. The direction improved, yet positive earnings are still absent.
The market value of the business moved from 4.9 billion dollars to 4.4 billion dollars, or −9.6%. Investors responded cautiously to the improvement in the business.
Conclusion
The indicators form a favorable picture of business development. The positive side is supported by an improving EBITDA margin, improving net profitability and a stable gross margin. Further direction will depend on top-line growth, operating profitability, and net income.
Annual Income Statement Amicus Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
4.43 B | 2.91 B | 3.86 B | 3.95 B | 2.55 B | 4.9 B | 2.18 B | 2.17 B | 2.46 B | 1.22 B | 664 M | 572 M | 145 M | 167 M | 226 M |
Shares |
308 M | 304 M | 295 M | 289 M | 271 M | 259 M | 240 M | 186 M | 153 M | 226 M | 110 M | 74.4 M | 51.3 M | 45.6 M | 34.6 M |
Historical Prices |
14.3 | 9.57 | 13.1 | 13.7 | 9.41 | 18.9 | 8.84 | 12 | 16.2 | 5.5 | 6.04 | 7.69 | 2.73 | 3.8 | 6.5 |
Net Income |
-27.1 M | -56.1 M | -152 M | -237 M | -250 M | -277 M | -356 M | -349 M | -284 M | -200 M | -132 M | -68.9 M | -59.6 M | -48.8 M | -44.4 M |
Revenue |
634 M | 528 M | 399 M | 329 M | 306 M | 261 M | 182 M | 91.2 M | 36.9 M | 4.96 M | - | 1.22 M | 363 K | 18.4 M | 21.4 M |
Cost of Revenue |
72.9 M | 52.9 M | 37.3 M | 38.6 M | 34.5 M | 31 M | 22 M | 14.4 M | 6.24 M | 833 K | - | - | - | - | - |
Gross Profit |
561 M | 475 M | 362 M | 291 M | 271 M | 230 M | 160 M | 76.8 M | 30.7 M | 4.12 M | - | - | 363 K | - | 21.4 M |
Operating Income |
32.8 M | 24.9 M | -77.2 M | -212 M | -206 M | -247 M | -304 M | -329 M | -442 M | -182 M | -130 M | -68.7 M | -64.2 M | -52.9 M | -50.9 M |
Interest Expense |
10.2 M | -9.44 M | -15.9 M | 4.18 M | 32.5 M | 22.4 M | 18.9 M | 22.4 M | 17.2 M | 5.4 M | 1.58 M | 1.48 M | 46 K | 89 K | 148 K |
EBITDA |
40.2 M | 33.4 M | -69.3 M | -207 M | -200 M | -238 M | -296 M | -321 M | -207 M | -179 M | -124 M | -67.1 M | -60.5 M | -51.2 M | -49.3 M |
Operating Expenses |
528 M | 450 M | 439 M | 503 M | 477 M | 477 M | 461 M | 402 M | 242 M | 186 M | 126 M | 69.9 M | 62.6 M | 71.3 M | 72.3 M |
General and Administrative Expenses |
383 M | 323 M | 275 M | 213 M | 193 M | 156 M | 170 M | 127 M | 88.7 M | 71.2 M | 47.3 M | 20.7 M | 18.9 M | 19.4 M | 19.9 M |
All numbers in USD currency
Quarterly Income Statement Amicus Therapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
308 M | 308 M | 308 M | 299 M | 305 M | 304 M | 303 M | 294 M | 296 M | 293 M | 291 M | 281 M | 289 M | 292 M | 288 M | 279 M | 267 M | 266 M | 264 M | 262 M | 259 M | 258 M | 257 M | 255 M | 255 M | 238 M | 214 M | 189 M | 189 M | 189 M | 176 M | 167 M | 161 M | 143 M | 143 M | 143 M | 141 M | 129 M | 125 M | 125 M | 119 M | 100 M | 95.7 M | 95.6 M | 78.9 M | 67.2 M | 64.4 M | 62 M | 49.6 M | 49.6 M | 49.6 M | 49.6 M | 48.5 M | 46.9 M | 37.9 M | 34.7 M | 35 M | 34.5 M | 34.5 M |
Net Income |
17.3 M | -24.4 M | -21.7 M | - | -6.73 M | -15.7 M | -48.4 M | - | -21.6 M | -43.2 M | -52.9 M | - | -33.3 M | -62.2 M | -85.3 M | - | -50.3 M | -51.2 M | -65.7 M | -71.4 M | -64 M | -52.5 M | -88.9 M | -89.7 M | -61.8 M | -84.6 M | -120 M | -78.1 M | -159 M | -61.8 M | -49.9 M | -69.2 M | -112 M | -48.1 M | -55 M | -58.6 M | -46.7 M | -51 M | -43.7 M | -42.9 M | -37.8 M | -27.1 M | -24.3 M | -21.2 M | -17.1 M | -14.6 M | -15.9 M | -12.2 M | -14.6 M | -15.3 M | -17.5 M | -10 M | -16.3 M | -9.34 M | -13.1 M | -8.66 M | -9.76 M | -12.6 M | -13.4 M |
Revenue |
169 M | 155 M | 125 M | - | 142 M | 127 M | 110 M | - | 104 M | 94.5 M | 86.3 M | - | 81.7 M | 80.7 M | 78.7 M | - | 79.5 M | 77.4 M | 66.4 M | 70.6 M | 67.4 M | 62.4 M | 60.5 M | 55.3 M | 48.8 M | 44.1 M | 34 M | 32.6 M | 20.6 M | 21.3 M | 16.7 M | - | 10.9 M | 7.16 M | 4.17 M | - | - | - | - | - | - | - | - | - | 293 K | 475 K | 456 K | - | 39 K | - | - | - | 18.4 M | 10.6 M | 7.77 M | - | 5.8 M | 4.04 M | 5.97 M |
Cost of Revenue |
19.5 M | 15.2 M | 11.7 M | - | 13.3 M | 11.3 M | 13.6 M | - | 9.95 M | 9.11 M | 6.94 M | - | 13.4 M | 8.2 M | 7.58 M | - | 11.7 M | 8.38 M | 6.54 M | - | 8.4 M | 6.68 M | 6.55 M | - | 5.6 M | 5.37 M | 4.06 M | - | 4.31 M | 3.14 M | 2.62 M | - | 1.79 M | 1.06 M | 775 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
150 M | 139 M | 114 M | - | 128 M | 115 M | 96.8 M | - | 93.6 M | 85.4 M | 79.3 M | - | 68.3 M | 72.5 M | 71.1 M | - | 67.8 M | 69 M | 59.9 M | - | 59 M | 55.7 M | 54 M | - | 43.2 M | 38.8 M | 30 M | - | 16.3 M | 18.2 M | 14.1 M | - | 9.08 M | 6.1 M | 3.39 M | - | 1.78 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
34.3 M | -9.47 M | -7.95 M | - | 21.7 M | 15 M | -27.7 M | - | -17 M | -18.9 M | -37.6 M | - | -33.8 M | -60.6 M | -75.3 M | - | -42.4 M | -38.8 M | -53.1 M | - | -52.8 M | -51.3 M | -78.1 M | - | -57.3 M | -76.4 M | -81.3 M | - | -156 M | -46.9 M | -56.2 M | - | -275 M | -47.1 M | -52 M | - | -44.9 M | -48.5 M | -43 M | - | -38 M | -26.9 M | -24.1 M | - | -16.8 M | -14.3 M | -15.6 M | - | -15.1 M | -16 M | -17.3 M | - | -16.9 M | -9.35 M | -10.7 M | - | -13.1 M | -14.7 M | -10 M |
Interest Expense |
10.9 M | 1.02 M | 550 K | - | -3.26 M | -3.72 M | -4.97 M | - | 3.83 M | -10.9 M | 11.8 M | - | 9.62 M | 8.26 M | 8.15 M | - | 8.16 M | 8.15 M | 7.99 M | - | 6.78 M | 3.64 M | 3.73 M | - | 4.03 M | 4.62 M | 6.45 M | - | 4.72 M | 4.56 M | 4.49 M | - | 4.35 M | 4.18 M | 4.29 M | - | 1.52 M | 1.06 M | 945 K | - | 17 K | 338 K | 372 K | - | 377 K | 374 K | 355 K | - | 7 K | 9 K | 10 K | - | 19 K | 15 K | 43 K | - | 32 K | 41 K | 48 K |
EBITDA |
36.1 M | -7.62 M | -6.12 M | - | 23.8 M | 17.1 M | -25.6 M | - | -14.8 M | -16.7 M | -36.4 M | - | -32.6 M | -59.3 M | -73.9 M | - | -40.9 M | -37.3 M | -51.5 M | - | -50.3 M | -49.3 M | -76.3 M | - | -56.2 M | -75.3 M | -80.3 M | - | -155 M | -46 M | -55.2 M | - | -274 M | -46.2 M | -51.2 M | - | -44 M | -47.8 M | -42.3 M | - | -37.6 M | -26.6 M | -23.6 M | - | -16.4 M | -13.9 M | -15.2 M | - | -14.7 M | -15.6 M | -16.8 M | - | -16.5 M | -8.9 M | -10.3 M | - | -12.8 M | -14.3 M | -9.56 M |
Operating Expenses |
115 M | 149 M | 122 M | - | 107 M | 100 M | 125 M | - | 111 M | 104 M | 117 M | - | 102 M | 133 M | 146 M | - | 110 M | 108 M | 113 M | - | 112 M | 107 M | 132 M | - | 100 M | 115 M | 111 M | - | 172 M | 65.1 M | 70.3 M | - | 284 M | 53.2 M | 55.4 M | - | 46.7 M | 48.5 M | 43 M | - | 38 M | 26.9 M | 24.1 M | - | 17.1 M | 14.7 M | 16.1 M | - | 15.2 M | 16 M | 17.3 M | - | 16.9 M | 20 M | 18.5 M | - | 18.9 M | 18.8 M | 16 M |
General and Administrative Expenses |
90 M | 84.5 M | 91.8 M | - | 75.1 M | 73.6 M | 88 M | - | 65.7 M | 65.4 M | 74 M | - | 47.3 M | 53.4 M | 58.1 M | - | 46.1 M | 42.3 M | 46.7 M | - | 37.8 M | 34.7 M | 40.2 M | - | 39.7 M | 42.6 M | 44.3 M | - | 31.9 M | 29.2 M | 27.4 M | - | 21.6 M | 19.3 M | 19.1 M | - | 17.5 M | 19.3 M | 15.7 M | - | 15.4 M | 8.28 M | 6.43 M | - | 5.27 M | 4.75 M | 5.18 M | - | 4.64 M | 4.83 M | 4.82 M | - | 5 M | 5.82 M | 4.1 M | - | 4.84 M | 6.72 M | 4.4 M |
All numbers in USD currency
The income statement is one of the three key financial reports of a company Amicus Therapeutics (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
USA
Canada
China
Britain
France
Israel
Germany
Russia
Belgium
Cayman-islands
